VOYDEYA (Alexion Pharmaceuticals Australasia Pty Ltd)
Product name
VOYDEYA
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
danicopan
Registration type
NCE/ NBE
Indication
VOYDEYA is indicated as an add-on to ravulizumab or eculizumab for the treatment of the signs or symptoms of extravascular haemolysis (EVH) in adult patients with paroxysmal nocturnal haemoglobinuria (PNH).